Federal contract award
75A50123C00060
THE DEVELOPMENT OF A MULTIMODAL ANTIBODY PLATFORM TO EXTEND THE WINDOW OF IMMUNOTHERAPEUTIC INTERVENTION. THE OVERALL OBJECTIVE OF THE WORK OUTLINED IN THIS CONTRACT IS TO CRITICALLY EVALUATE THE UTILITY OF THE VHH AS A PLATFORM MCM TECHNOLOGY FOR VI
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | 3650 — Chemical and Pharmaceutical Products Manufacturing Machinery |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $33.1M |
| Current contract value | $33.1M |
| Potential contract value / ceiling | $317.6M |
| Start date | Sep 22, 2023 |
| Current end date | Sep 30, 2027 |
| Potential end date | Sep 30, 2034 |
| Latest award activity | Jul 28, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 7 of 7 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jul 28, 2026 | P00006 | $1.9M | THE DEVELOPMENT OF A MULTIMODAL ANTIBODY PLATFORM TO EXTEND THE WINDOW OF IMMUNOTHERAPEUTIC INTERVENTION. THE OVERALL OBJECTIVE OF THE WORK OUTLINED IN THIS CONTRACT IS TO CRITICALLY EVALUATE THE UTILITY OF THE VHH AS A PLATFORM MCM TECHNOLOGY FOR VI |
| May 19, 2026 | P00005 | $0 | THE DEVELOPMENT OF A MULTIMODAL ANTIBODY PLATFORM TO EXTEND THE WINDOW OF IMMUNOTHERAPEUTIC INTERVENTION. THE OVERALL OBJECTIVE OF THE WORK OUTLINED IN THIS CONTRACT IS TO CRITICALLY EVALUATE THE UTILITY OF THE VHH AS A PLATFORM MCM TECHNOLOGY FOR VI |
| Jul 15, 2025 | P00004 | $4.6M | THE DEVELOPMENT OF A MULTIMODAL ANTIBODY PLATFORM TO EXTEND THE WINDOW OF IMMUNOTHERAPEUTIC INTERVENTION. THE OVERALL OBJECTIVE OF THE WORK OUTLINED IN THIS CONTRACT IS TO CRITICALLY EVALUATE THE UTILITY OF THE VHH AS A PLATFORM MCM TECHNOLOGY FOR VI |
| Jan 7, 2025 | P00003 | $0 | THE DEVELOPMENT OF A MULTIMODAL ANTIBODY PLATFORM TO EXTEND THE WINDOW OF IMMUNOTHERAPEUTIC INTERVENTION. THE OVERALL OBJECTIVE OF THE WORK OUTLINED IN THIS CONTRACT IS TO CRITICALLY EVALUATE THE UTILITY OF THE VHH AS A PLATFORM MCM TECHNOLOGY FOR VI |
| Mar 19, 2024 | P00002 | $17.0M | THE DEVELOPMENT OF A MULTIMODAL ANTIBODY PLATFORM TO EXTEND THE WINDOW OF IMMUNOTHERAPEUTIC INTERVENTION. THE OVERALL OBJECTIVE OF THE WORK OUTLINED IN THIS CONTRACT IS TO CRITICALLY EVALUATE THE UTILITY OF THE VHH AS A PLATFORM MCM TECHNOLOGY FOR VI |
| Dec 7, 2023 | P00001 | $0 | THE DEVELOPMENT OF A MULTIMODAL ANTIBODY PLATFORM TO EXTEND THE WINDOW OF IMMUNOTHERAPEUTIC INTERVENTION. THE OVERALL OBJECTIVE OF THE WORK OUTLINED IN THIS CONTRACT IS TO CRITICALLY EVALUATE THE UTILITY OF THE VHH AS A PLATFORM MCM TECHNOLOGY FOR VI |
| Sep 22, 2023 | 0 | $9.6M | THE DEVELOPMENT OF A MULTIMODAL ANTIBODY PLATFORM TO EXTEND THE WINDOW OF IMMUNOTHERAPEUTIC INTERVENTION. THE OVERALL OBJECTIVE OF THE WORK OUTLINED IN THIS CONTRACT IS TO CRITICALLY EVALUATE THE UTILITY OF THE VHH AS A PLATFORM MCM TECHNOLOGY FOR VI |
Estimated positioning window
Sep 30, 2033 – Mar 30, 2034
25/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 25/100. Available recorded signals: 20 points.
- Contract end 2034-09-30 (2890 days from calculation)
- +5 points
- 1 historical awards in this buyer and category group
- +0 points
- 7 recorded award transactions
- +10 points
- Latest award action: 2026-07-28
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +0 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.